Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Inscopix to Leverage its Brain Mapping Platform to Pursue Novel Therapeutic Targets in Parkinson's Disease

PALO ALTO, Calif.

Inscopix today announced a new research effort that leverages its brain mapping platform and single-cell transcriptomics for a more nuanced understanding of Parkinson’s disease (PD) and identification of novel targets for therapeutic development. The research will be conducted in collaboration with Dr. Evan Macosko at the Broad Institute of MIT and Harvard, a leading expert in transcriptomics.

The research builds on a 2018 study published in Nature by Stanford researchers that used Inscopix’s miniature microscope platform to identify changes in neural activity patterns in brain circuits that regulate movement, in a PD mouse model. The model is characterized by the loss of dopamine neurons, a hallmark of the disease, and is routinely used in preclinical research.

Leveraging each organization’s expertise, the research will determine whether changes in neuronal activity can be correlated at a cellular level with changes in gene expression that might result from the depletion of dopamine in the mouse model. The investigators hope that by combining the functional and gene expression datasets, they will derive a multidimensional and comprehensive understanding of PD and also set the foundation for the development of precision neurotherapeutics for the disease through the identification of novel, cell-type-specific druggable targets. The Macosko Lab and Inscopix will share rights to any discoveries made through the collaboration.

“Single-cell transcriptomics and brain mapping have each demonstrated the potential to increase our understanding of neurological conditions, such as Parkinson’s disease, and bringing them together could help us make even greater strides forward,” Kunal Ghosh, Ph.D., chief executive officer of Inscopix. “We look forward to expanding our research into PD with the Macosko Lab, with the goal of paving the way for therapeutic programs that can be de-risked at earlier stages of development.”

PD has been selected as the first disease area for this pilot program to assess the potential of utilizing both brain mapping and transcriptomics to advance new therapeutic approaches. If successful, Inscopix and the Macosko Lab will assess the potential to collaborate surrounding additional neurological conditions.

According to the Parkinson’s Foundation, Parkinson’s disease affects over 10 million people globally.

About nVoke

nVoke is Inscopix’s state-of-the-art miniature microscope-based solution for simultaneous imaging and manipulation of large-scale neural circuit dynamics in freely behaving subjects. With nVoke, researchers at leading research institutions worldwide are pushing the frontiers of neuroscience and asking entirely new questions about how neural circuits shape cognition and behavior in health and disease. For more information, please visit: https://www.inscopix.com/nVoke.

About Inscopix, Inc.

Inscopix empowers the development of next-generation therapeutics for difficult-to-treat brain disorders by enabling innovative research and predictive preclinical therapeutic development. Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits. These objective, quantitative and in-brain assays are catalyzing unprecedented insights into disease mechanisms and have been shown to be more accurate at predicting clinical efficacy than animal behavior when testing a therapeutic candidate’s capacity to bring the brain back to a normal state. Inscopix’s partner and customer discoveries help decode the brain, inform deeper understanding of mechanisms of action and enable the screening of drugs based on efficacy. For more information, please visit http://www.inscopix.com.

Inscopix Media Contact
Ian Stone
Senior Vice President, Canale Communications
(619) 518-3518
ian@canalecomm.com

Tags:




×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.